The companies will jointly develop 4D bio-engineered corneal grafts for diseases requiring endothelial keratoplasty and natural lenticule grafts
Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio’s two corneal transplant products and holds exclusive worldwide marketing rights for these products
JENA, Germany and WINSTON SALEM, North Carolina, July 18, 2022 /PRNewswire/ — Carl Zeiss Meditec and Accurate Bioa regenerative medicine company advancing the use of bioprinted tissues and organs, today announced that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients requiring endothelial keratoplasty and natural duckweed transplants for the treatment of keratoconus and vision correction.
Under the terms of the agreement, Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio’s two corneal transplant products and holds exclusive worldwide marketing rights for these products. Financial terms were not disclosed.
“This investment in Precise Bio should complement our leading portfolio of cataract and corneal refraction workflow solutions,” said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit at Carl Zeiss Meditec. “The technology has the potential to advance treatment options for corneal diseases, as well as elective procedures, which helps optimize patient care.”
“We are excited about this partnership which builds on our successful and ongoing collaboration with ZEISS for the development of corneal tissue to address unmet needs in the field of ophthalmology,” said Aryeh Batt, co-founder and CEO of Precise Bio. “This strategic agreement builds on ZEISS’ global leadership in ophthalmology and Precise’s innovative and unique 4D biofabrication platform technology. We are confident that the synergy between the two companies will enable us to develop breakthrough solutions for patient sight recovery, bringing hope to hundreds of millions of patients worldwide.”
Precise Bio combines engineering, biomaterials, cell technology, bioengineering and 3D printing into an unparalleled 4D bio-manufacturing platform for transplantable organs and tissues. The company’s proprietary platform technology enables tissue to be fabricated by “imprinting” cells with single-cell resolution and spatial precision, enabling complex organoid constructs with both structural integrity and long-term cell viability. Overcoming multiple technological challenges, Precise Bio’s 4D biofabrication technology makes it possible to reliably extend tissue engineering to clinical use and produce large quantities in a reproducible, quality-controlled and cost-effective process. Precise Bio’s ophthalmology pipeline consists of three products, the two corneal products that are the subject of the collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which have demonstrated good results. in animal models. The Company’s ophthalmic products are aimed at global markets exceeding $10 billion annually.
Bio-engineered tissues composed of human cells and natural materials, mimicking the anatomical structure and natural tissue components, can replace damaged or diseased tissue, substitute for donor tissue where there is a lack of tissue, or solve unmet therapeutic needs.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the German Stock Exchange MDAX and TecDAX, is one of the world’s leading medical technology companies. The Company provides innovative technologies and application-driven solutions designed to help physicians improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, for diagnosing and treating eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group achieved revenue of €1,646.8 million in fiscal year 2020/21 (to September 30).
The Group’s head office is located in Jena, Germanyand has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the UNITED STATES, Japan, Spain and France. The Center for Application and Research (CARIn) of Bengaluru, India and the Carl Zeiss Innovations Research and Development Center in Shanghai, China, strengthen the Company’s presence in these developing economies. Approximately 41% of the shares of Carl Zeiss Meditec AG are free float. The rest approx. 59% are held by Carl Zeiss AG, one of the world’s leading optics and optoelectronics groups.
For more information visit: www.zeiss.com/med
About Precise Bio
Precise Bio develops regenerative medicine therapies that can transform patient care across a wide range of medical indications. Precise Bio’s proprietary and revolutionary 4D biofabrication platform overcomes the limitations of existing inkjet and extrusion printers and paves the way for the fabrication of clinically viable tissues and organs. The Company’s initial product portfolio is focused on ophthalmology and includes fabricated functional corneal grafts, intrastromal lenticules for the treatment of keratoconus and vision correction, and a retinal implant for age-related macular degeneration . The company also has prior R&D programs to address unmet needs in additional medical indications, which are limited by the number of donor tissues and organs available, or where today’s critical health issues may be resolved using Precise Bio’s natural and hyper-precise technology.
Precise Bio was founded in 2016 by Prof. Antoine AtalaMD, Director of the Wake Forest Institute of Regenerative Medicine (WFIRM), Prof. Shay SokerPhD, from WFIRM and Mr. Aryeh Batt, who developed the company’s transformative laser printing technology. The Company operates from two centers, Winston Salem, North Carolina and Modi’in, Israel. For more information, please visit www.precise-bio.com.
Contact Precise Bio for investors:
Telephone: +972 76 539 1001
Accurate Bio press / media contact:
Global Media Liaison
Telephone: +972 52 598 9892
ZEISS contact for investors:
Investor Relations Director
Carl Zeiss Meditec SA
Telephone: +49 3641 220-116
ZEISS contact for press / media:
Head of Global Communications Ophthalmic Devices
Carl Zeiss Meditec
Telephone: +1 925 719 7825
SOURCE Bio Precise